Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Wholesalers’ Price Negotiations Likely to Be Carried Over to New Fiscal Year; Unsettlement Rates Could Hit Double-Digit Figures
March 12, 2013
- Kyowa Kirin to Start Constructing Manufacturing Plant in Gunma in May
March 12, 2013
- Hisamitsu to File for Chronic Pain for Fentos Tape in 2013
March 12, 2013
- Nihon Chouzai Obtains Loan from Development Bank of Japan to Strengthen Production Base for Generic Drugs
March 12, 2013
- Dolutegravir Shows Significant Superior Efficacy Compared to Raltegravir in PIII Study: Shionogi
March 12, 2013
- Qol Senior Managing Director Takada Proposes Utilization of CSO for Long-Listed Products and Generics
March 11, 2013
- Nippon Shinyaku Licenses OAB Drug from DSP, Aims for Launch of Nocturia Treatment in 2019
March 11, 2013
- Takeda Files for UC and CD Drug Vedolizumab in Europe
March 11, 2013
- Otsuka, Lundbeck to Expand Collaboration, Copromote Abilify in US, Europe
March 11, 2013
- Ethical Drug Sales Up 4.8% in January: Crecon Report
March 11, 2013
- Astellas, UCB Japan Launch RA Treatment Cimzia
March 11, 2013
- NBI Calls for Proper Use of Prazaxa due to Unsatisfactory Compliance with Blue Letter
March 11, 2013
- Sandoz Will See Accelerated Growth of Japan Operations in 2013: Global Head
March 11, 2013
- Eisai to Reorganize Sales Force in Japan to Secure Aricept Market Share
March 8, 2013
- With Growing Competition from Foreign Drug Makers, Takeda Interested in Product Tie-ups: President Hasegawa
March 8, 2013
- Yakult Enters Biosimilars Business, Ties Up with UMN and API
March 7, 2013
- Novartis Withdraws Application for Glivec for PAH in Japan
March 7, 2013
- Ajinomoto to Acquire US Contract Biologic Manufacturer Althea
March 7, 2013
- Sawai's New Plant Starts Operation, Raising Annual Production Capacity to 8 Billion Tablets
March 6, 2013
- Nichi-Iko's New Factory Completed in Toyama, Production Capacity to Reach 7-8 Billion Tablets a Year
March 6, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…